晚期胃腸間質(zhì)瘤馮繼鋒課件

晚期胃腸間質(zhì)瘤(GIST)的藥物治疔馮繼鋒教授江蘇省腫瘤醫(yī)院南京醫(yī)科大學(xué)附屬腫瘤醫(yī)院晚期胃腸間質(zhì)瘤(GIST)的藥物治疔1GsT的流行病學(xué)●胃腸道(G)最常見的肉瘤●間葉源(結(jié)締組織)性腫瘤●占所有胃腸道腫瘤的0.2%,但占胃腸道肉瘤的80%高發(fā)年齡為40-60歲●男、女發(fā)病率相當(dāng),但有些報(bào)道提示男性發(fā)病率略高●最近GST被確認(rèn)為具有獨(dú)立臨床和組織病理學(xué)特征的腫瘤●以往曾誤診為平滑肌肉瘤/其他梭形細(xì)胞癌●GIST的年發(fā)病率為14.5/100萬(與慢性粒細(xì)胞性白血病相似);患病率為129/100萬。Finersgistgeea2Kratomaa.AnnOnca2019:13:157.Abstac:577oGsT的流行病學(xué)2GST的流行病學(xué)GIST可以發(fā)生在胃腸道的任何部位、腹腔內(nèi)其他部位或后腹膜結(jié)腸Colon其他部位(直腸、食管、腸系膜后腹膜)10%15%25%50%小腸胃GST的流行病學(xué)3轉(zhuǎn)移性G|ST中位生存期SWOGS861659627YearsafterregistrationBlankeetal.Abstract7.GICancerssymposium,2019轉(zhuǎn)移性G|ST中位生存期4轉(zhuǎn)移性GST傳統(tǒng)化療臨床研究匯總NumberofPartialResponseRegimenPatientsDOX+DtICDOX+dTIC+/-IF0(15%)IF+VP-160(0%)Paclitaxel30057(7%)GemcitabineLiposomaldox50(0%)DOX0(0%)DOXordocetaxel(0%)High-doseIF260(0%)EPI+IF0(0%)arIous4(10%)DTIC/MMC/DOX,CDDP/GM-CSFTemozolamide190(0%)TOTAL28019(6.8%轉(zhuǎn)移性GST傳統(tǒng)化療臨床研究匯總5晚期胃腸間質(zhì)瘤馮繼鋒課件6晚期胃腸間質(zhì)瘤馮繼鋒課件7晚期胃腸間質(zhì)瘤馮繼鋒課件8晚期胃腸間質(zhì)瘤馮繼鋒課件9晚期胃腸間質(zhì)瘤馮繼鋒課件10晚期胃腸間質(zhì)瘤馮繼鋒課件11晚期胃腸間質(zhì)瘤馮繼鋒課件12晚期胃腸間質(zhì)瘤馮繼鋒課件13晚期胃腸間質(zhì)瘤馮繼鋒課件14晚期胃腸間質(zhì)瘤馮繼鋒課件15晚期胃腸間質(zhì)瘤馮繼鋒課件16晚期胃腸間質(zhì)瘤馮繼鋒課件17晚期胃腸間質(zhì)瘤馮繼鋒課件18晚期胃腸間質(zhì)瘤馮繼鋒課件19晚期胃腸間質(zhì)瘤馮繼鋒課件20晚期胃腸間質(zhì)瘤馮繼鋒課件21晚期胃腸間質(zhì)瘤馮繼鋒課件22晚期胃腸間質(zhì)瘤馮繼鋒課件23晚期胃腸間質(zhì)瘤馮繼鋒課件24晚期胃腸間質(zhì)瘤馮繼鋒課件25晚期胃腸間質(zhì)瘤馮繼鋒課件26晚期胃腸間質(zhì)瘤馮繼鋒課件27晚期胃腸間質(zhì)瘤馮繼鋒課件28晚期胃腸間質(zhì)瘤馮繼鋒課件29晚期胃腸間質(zhì)瘤馮繼鋒課件30晚期胃腸間質(zhì)瘤馮繼鋒課件31晚期胃腸間質(zhì)瘤馮繼鋒課件32晚期胃腸間質(zhì)瘤馮繼鋒課件33晚期胃腸間質(zhì)瘤馮繼鋒課件34晚期胃腸間質(zhì)瘤馮繼鋒課件35晚期胃腸間質(zhì)瘤馮繼鋒課件36晚期胃腸間質(zhì)瘤馮繼鋒課件37晚期胃腸間質(zhì)瘤馮繼鋒課件38晚期胃腸間質(zhì)瘤馮繼鋒課件39晚期胃腸間質(zhì)瘤馮繼鋒課件40晚期胃腸間質(zhì)瘤馮繼鋒課件41晚期胃腸間質(zhì)瘤馮繼鋒課件42晚期胃腸間質(zhì)瘤馮繼鋒課件43晚期胃腸間質(zhì)瘤馮繼鋒課件44晚期胃腸間質(zhì)瘤馮繼鋒課件45晚期胃腸間質(zhì)瘤馮繼鋒課件46晚期胃腸間質(zhì)瘤馮繼鋒課件47晚期胃腸間質(zhì)瘤馮繼鋒課件48晚期胃腸間質(zhì)瘤馮繼鋒課件49晚期胃腸間質(zhì)瘤馮繼鋒課件50晚期胃腸間質(zhì)瘤馮繼鋒課件51晚期胃腸間質(zhì)瘤馮繼鋒課件52晚期胃腸間質(zhì)瘤馮繼鋒課件53晚期胃腸間質(zhì)瘤馮繼鋒課件54晚期胃腸間質(zhì)瘤